Lung squamous cell carcinoma

Combining the zero-phase application and preliminary basic research, the company passed the lung cancer clinical trial ethics at the Cancer Hospital of the Chinese Academy of Medical Sciences on August 9, 2018. On September 12, 2018, the "Single-arm, Open-labeled, Multicenter Phase Ib/IIa Clinical Research on the CHA for Injection for advanced lung cancer" was registered (Registration number: CTR20181332) and made public on the Drug Clinical Trial Registration and Information Disclosure Platform. The indications for this clinical trial are: advanced lung squamous cell carcinoma, advanced lung adenocarcinoma, and advanced small cell lung cancer patients without effective treatment.

Considering that  CHA for injection has demonstrated strong anti-tumor activity in the indication of squamous cell lung cancer, proceeding from the unmet clinical needs, combining the results of mechanism research and the communication opinions with clinical experts, the company has adjusted the original clinical trial protocol and plans to re-initiate the clinical research on the treatment of squamous cell lung cancer with CHA for injection.

Esophageal squamous cell carcinoma

The research team led by Academician Jiang Jiandong has conducted in-depth research on the anti-tumor mechanism of chlorogenic acid, especially the pharmacodynamics and mechanism of chlorogenic acid in the treatment of esophageal squamous cell carcinoma. Based on preliminary exploration of clinical trial and fundamental pharmacodynamic studies, CHA for injection has demonstrated strong anti-tumor activity against esophageal carcinoma, particularly in inhibiting recurrence and metastasis.  The latest research by Academician Jiang’s team indicates that CHA can downregulate PD-L1 expression in esophageal carcinoma through the IFN-γ signaling pathway. Notch1 is one of the targets of CHA, which inhibits the clonal formation, invasion, and metastasis of esophageal carcinoma cells by acting on Notch1. This provides a molecular theoretical basis for new methods of esophageal cancer treatment.  

Plans are underway to conduct a clinical trial targeting patients with advanced esophageal squamous carcinoma based on the above research.

References：

1、Zhan Y, et al. Chlorogenic acid inhibits esophageal squamous cell carcinoma growth in vitro and in vivo by downregulating the expression of BMI1 and SOX2. Biomed Pharmacother. 2020 Jan;121:109602.

2、詹芸,李瑞,李晓琳,等.绿原酸通过IFN-γ信号通路抑制食管癌细胞中PD-L1的表达[J].药学学报,2021,56(06):1599-1605.

3、詹芸,李瑞,蒋建东,等.绿原酸通过下调Notch1的表达抑制食管癌细胞的克隆形成和侵袭转移[J].中国医药生物技术,2021,16(03):201-208.